Switching off injectables: what ATTAIN-MAINTAIN tells us about oral GLP-1 receptor agonists

Persistence with injectable GLP-1 receptor agonists remains a significant barrier to long-term weight loss maintenance, with early discontinuation well documented in real-world cohorts.² If the weight reduction achieved on injectables is to mean anything beyond the duration of treatment, the field needs alternatives for patients who cannot or will not stay on them. An oral GLP-1 receptor agonist is the obvious candidate, and ATTAIN-MAINTAIN, published this month in Nature Medicine, addresses this directly.¹

The trial:¹

376 patients who had completed 72 weeks of either tirzepatide or semaglutide in SURMOUNT-5 were randomised to oral orforglipron or placebo for 52 weeks, transitioning directly from their injectable maximum tolerated dose. The primary endpoint was percentage of SURMOUNT-5 weight loss preserved at week 52.

• Post-tirzepatide cohort: orforglipron preserved 74.7% of the original weight reduction versus 49.2% on placebo (p<0.001)

• Post-semaglutide cohort: 79.3% versus 37.6% on placebo (p<0.001)

Cardiometabolic gains including HbA1c, systolic blood pressure, waist circumference and lipids held across both groups. The transition was well tolerated, with GI adverse events under 11% in the first four weeks despite starting directly at 12mg, and no dose reductions needed.

ATTAIN-MAINTAIN · Nature Medicine 2026

Weight loss preserved at 52 weeks after switching to oral GLP-1 receptor agonist

Post-tirzepatide cohort

Oral GLP-1 RA74.7% p<0.001

Placebo49.2%

Post-semaglutide cohort

Oral GLP-1 RA79.3% p<0.001

Placebo37.6%

Primary endpoint: percentage of SURMOUNT-5 weight loss preserved at week 52 (plateau participants, treatment-regimen estimand). Drug class names used per editorial policy. Source: Aronne LJ et al. Nature Medicine 2026. doi:10.1038/s41591-026-04386-7

A finding worth sitting with:¹

There is one finding outside the primary endpoint worth sitting with. Both cohorts ended the trial at exactly the same mean body weight: 95.9 kg. Different starting drugs, different weight trajectories through SURMOUNT-5, same number at week 52. The authors raise cautiously the possibility of a biologically defended weight.

Speculative from a single trial of one agent, but it fits what the weight-reduced state literature has been building toward for years, around adaptive thermogenesis and physiological resistance to sustaining weight loss below a defended threshold. It also surfaces a question the field has not resolved: what does maintenance actually mean in obesity? This paper runs four separate endpoints because there is no agreed definition. Expect the same in every maintenance trial that follows.

Limitations:¹

The limitations matter. Lilly-funded, Lilly authors, Lilly's drug. No active comparator, so this tells you switching beats stopping, not how it compares with continuing the injectable. Rescue orforglipron was available from week 24, leaving only 31% of placebo patients in the tirzepatide cohort and 18% in the semaglutide cohort reaching week 52 without active intervention. US only, predominantly white, one year, no type 2 diabetes. Orforglipron is not yet MHRA-approved.

Bottom line

Nothing changes in practice today. But this is the evidence base that will underpin the conversation when it does.¹

References

1. Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine 2026. https://doi.org/10.1038/s41591-026-04386-7

2. Gasoyan H et al. Early- and later-stage persistence with antiobesity medications: a retrospective cohort study. Obesity 2024;32:486–493.

Medicine Central is a clinical evidence review for UK primary care clinicians. Content reflects evidence current at time of publication and should be read alongside local formulary and clinical guidance. Guest contributors retain responsibility for the accuracy and originality of their work. Views expressed are the author's own and do not necessarily reflect those of Medicine Central. For healthcare professionals only.